Get the Stockscreener App
1.73
2.37%
0.04
After Hours:
1.64
-0.09
-5.20%
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Latest News
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) Secures EU Patent for FHAB Platform Technology - Defense World
Sonnet BioTherapeutics secures EU patent for FHAB technology - Pharmaceutical Technology
Sonnet BioTherapeutics Secures EU Patent for FHAB Technology - TipRanks
Sonnet BioTherapeutics Further Expands Global Intellectual - GlobeNewswire
Game-Changing Cancer Drug Technology Gets Major EU Patent ProtectionHere's Why It Matters - StockTitan
Sonnet BioTherapeutics begins trial combining SON-1010, trabectedin - MSN
Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - GlobeNewswire
Sonnet BioTherapeutics to expand trial of SON-1010 with trabectedin for solid tumours - Clinical Trials Arena
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas - Defense World
Sonnet BioTherapeutics Expands Phase 1 Study for SON-1010 - TipRanks
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to - GlobeNewswire
Sonnet BioTherapeutics Expands SON-1010 Phase 1 Trial to Combat Soft-Tissue Sarcoma - StockTitan
Why Sonnet BioTherapeutics (SONN) Shares Are Down 19% Today - MSN
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News Summary - Benzinga
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment - GlobeNewswire
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Corporate UpdateOn December 17, 2024, Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, released it - Defense World
Insights into Sonnet BioTherapeutics Q4 Earnings - Benzinga
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Sonnet BioTherapeutics Slashes Operating Costs 37% in FY2024, Advances Cancer Drug Pipeline - StockTitan
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Sonnet BioTherapeutics (NASDAQ: SONN) Announces $3.9 Million Registered Direct Offering and Private PlacementPrinceton, New Jersey, December 9, 2024 – Sonnet BioTherapeutics Holdings, Inc. (SONN), a clinical-stage company focusing on targeted i - Defense World
Sonnet BioTherapeutics (NASDAQ: SONN) Reports Positive Safety Data in SON-1010 Monotherapy Dose Escalation Trial - Defense World
Sonnet BioTherapeutics reports progress in cancer trial By Investing.com - Investing.com Nigeria
Sonnet BioTherapeutics reports progress in cancer trial - Investing.com India
Sonnet BioTherapeutics Announces $3.9 Million Registered - GlobeNewswire
Sonnet BioTherapeutics Secures $3.9M Strategic Financing Deal Through Mixed Securities Offering - StockTitan
Sonnet BioTherapeutics Announces Topline Safety Data - GlobeNewswire
Sonnet Bio's Cancer Drug Shows Promise: 48% Disease Control, One Patient's Tumor Shrinks 45% in Phase 1 Trial - StockTitan
Sonnet BioTherapeutics reports advances in cancer treatment drug By Investing.com - Investing.com Canada
Sonnet BioTherapeutics reports advances in cancer treatment drug - Investing.com India
Sonnet BioTherapeutics Announces Publication Detailing the - GlobeNewswire
Sonnet BioTherapeutics Unveils Breakthrough Cancer Drug Delivery System in Major Publication - StockTitan
Sonnet BioTherapeutics Holdings (STU:H3D) Financial Strengt - GuruFocus.com
Comfort Systems USA (FIX-N) QuotePress Release - The Globe and Mail
Sonnet BioTherapeutics’ $5 Million Common Stock Offering - Global Legal Chronicle
Sonnet BioTherapeutics Holdings (STU:H3D) Change In Receiva - GuruFocus.com
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment - GlobeNewswire
Sonnet BioTherapeutics Secures Crucial Patent for Novel Cancer Immunotherapy Pipeline | SONN Stock News - StockTitan
Sonnet BioTherapeutics (NASDAQ: SONN) Announces Issuance of U.S. Patent for Novel Immunotherapeutic Drug Candidates - Defense World
Sonnet BioTherapeutics secures US patent covering two drug candidates - Pharmaceutical Technology
Sonnet BioTherapeutics secures patent for cancer drug candidates By Investing.com - Investing.com Australia
SONN stock touches 52-week high at $9.9 amid market optimism - Investing.com Australia
Sonnet BioTherapeutics Prices of $5.0 Million Underwritten Public Offering - citybiz
Sonnet BioTherapeutics Announces Pricing of $5.0 Million - GlobeNewswire
Sonnet BioTherapeutics sets $5 million stock offering - Investing.com India
Sonnet BioTherapeutics sets $5 million stock offering By Investing.com - Investing.com UK
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):